FRα-targeted PDT in ovarian cancer: beyond cytotoxicity, an immunomodulatory therapy
Cell Signaling · 19.05.2026 · 4 (1) · 63
DOI: 10.46439/signaling.4.098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Signaling, online erschienen am 19.05.2026. Verfasst von Nadia Hage Ali und 4 weiteren Autor:innen. Die Arbeit nennt 66 Literaturangaben.
Abstract (Originalsprache)
In our recent published study entitled “Targeted Photodynamic Therapy using a Vectorized Photosensitizer coupled to a Folic Acid Analog induces Ovarian Tumor Cell Death and inhibits IL-6-mediated Inflammation”, we explore the effect of a new approach for the treatment of ovarian cancer. We found that photosensitizer coupled to an analog of folic acid (PSFAA) selectively accumulates in ovarian cancer cells and, upon light activation, induces an efficient photodynamic cytotoxicity. Moreover, we demonstrate that FRα-targeted PDT induces an inhibition of the pro-tumoral and immunosuppressive IL-6 cytokine secretion. The results support that FRα-targeted PDT not only eradicates residual ovarian tumor cells but could also modulate the immune microenvironment. In this commentary, we introduce more in-depth ovarian cancer immune background, summarize key findings of the published work, and discuss emerging questions and future research directions, focusing on FRα PDT-induced immune re-activation and its potential to re-sensitize ovarian cancer to immunotherapies.
Zitieren
APA
Ali, N. H., Stoup, N., Morales, O., Kerbage, Y., & Delhem, N. (2026). FRα-targeted PDT in ovarian cancer: beyond cytotoxicity, an immunomodulatory therapy. Cell Signaling, 4(1), 63. https://doi.org/10.46439/signaling.4.098
Vancouver
Ali NH, Stoup N, Morales O, Kerbage Y, Delhem N. FRα-targeted PDT in ovarian cancer: beyond cytotoxicity, an immunomodulatory therapy. Cell Signaling. 2026;4(1):63. doi:10.46439/signaling.4.098
BibTeX
@article{Ali2026,
author = {Ali, Nadia Hage and Stoup, Nicolas and Morales, Olivier and Kerbage, Yohan and Delhem, Nadira},
title = {FRα-targeted PDT in ovarian cancer: beyond cytotoxicity, an immunomodulatory therapy},
journal = {Cell Signaling},
year = {2026},
volume = {4},
number = {1},
pages = {63},
doi = {10.46439/signaling.4.098}
}
EUVIMED